Chi­na biotech start­up In­ven­tis­Bio bags a $19M round for ear­ly-stage R&D

The flow of ven­ture cash in and out of Chi­na’s biotech scene in­cludes a new $19 mil­lion round to­day for Shang­hai-based In­ven­tis­Bio, which has been lin­ing up a slate of can­cer ther­a­pies for Phase I de­vel­op­ment.

Mer­ck vet and com­pa­ny founder Yaolin Wang tells me that he left the glob­al phar­ma gi­ant in 2015 to start the com­pa­ny, which has been op­er­at­ing as a vir­tu­al out­fit with 7 staffers and a crew of sup­port staff at WuXi and oth­er CROs in the coun­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER